The National Comprehensive Cancer Network (NCCN) guidelines recommend using the 21‐gene assay to assist in the decision of whether chemotherapy is required after surgery for ER+/HER2− early breast cancer [18, 19]. This evidence concerns the gene ERBB2 and breast carcinoma.